cesses, its clonal architecture. And yet, as Voltaire hints, we have known thiswe have known the unpredictability of cancer outcomes in the clinic, the fact that two patients can have apparently identical cancers by every clinical measure and yet one die, one live. To understand clinical variability, we must embrace the heterogeneity of cancer genomes. In their complexity lie the myriad causative mutations, each defining cellular behaviors that in toto dictate a cancer's path. Histology, metastasis, treatment response, drug resistance-all are encoded in the cancer genome but in such intricacy that robustly decoding them requires sample sizes beyond those completed thus far. We must match cancer genomes to patients' clinical outcomes on a massive scale. We should start with clinical trials, but explore the systematic collation of genomic and clinical data from routine hospital care as sequencing enters the clinic. As the Global Alliance intends, we should openly discuss the ethical challenges, the clinical descriptors, the database infrastructure, the quality assurance that such an endeavor entails. With a knowledge bank of a million patients or more, cancer's many faces might become touchable.
What's Missing?
Janet D. Rowley
University of Chicago
The current cancer genome sequencing projects have already revealed a number of previously unknown recurring mutated genes and unsuspected translocations. Many of these have been confirmed by targeted analyses of large patient sample banks. These new genetic targets are important because they expand the number of potential therapeutic targets as well as increasing our understanding of the range of cell biological processes that contribute to malignant transformation. Simultaneously, we have become increasingly aware that perturbations of other systems, such as DNA modifications due to conversion of methylC to 5hydroxy-methylC and modifications of the histone tails of nucleosome components, can have a profound effect on the expression of ''normal'' genes as assessed by standard DNA analysis. We are just beginning to appreciate the impact of noncoding RNAs, both short and long on a host of genes. We need to focus on the role of these and other RNAs about which we are woefully ignorant, on the regulation of gene expression. In fact, in addition to mining the huge DNA sequencing database, constructing an equally robust database of histone modifications and RNA regulators of gene expression is a major challenge for the future. At present we have too limited a view of what a biologically complete analysis of the cancer ''genotype'' really encompases!
Thinking beyond Therapy

Bert Vogelstein and Kenneth Kinzler
Johns Hopkins University
The good news from genome-wide sequencing studies of cancer over the past 7 years is that there are only a limited number of genes (150) and pathways (12) that, when defective, are responsible for all common forms of human cancer (Vogelstein et al., Science 339, 1546 Science 339, -1558 . The bad news from these sequencing studies is that there are multiple ways for cancers to develop resistance to targeted therapeutics. Such studies have highlighted how difficult it will be to produce prolonged remissions, or cures, in patients with advanced cancers. On the other hand, our new appreciation of the cancer genome provides an opportunity to rethink our strategies for reducing cancer deaths in the long term. Deaths from most cancers are preventable: sequencing as well as clinical studies have shown that cancers take decades to develop and are only lethal at the end of this long process, once metastasis has occurred. This time frame provides a large window of opportunity for intervention prior to the onset of metastatic disease. Innovative molecular and imaging-based approaches for early detection based on the genetic alterations and consequent pathway disruptions can open this window. When combined with readily implementable measures for cancer prevention (Colditz et al., Sci. Transl. Med. 4, 127rv4) , these approaches have the capacity to reduce deaths from cancer by 75% in the foreseeable future-even without any new therapies.
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Cancer Genomics in Context
Lynda Chin
MD Anderson Cancer Center
The Cancer Genome Atlas (TCGA) has been a defining project of its era for cancer medicine. Its impact rests on the creation of a high quality and comprehensive (up-to-date) genomic reference that catalyzes identification of promising therapeutic and diagnostic targets and also drives fundamental discoveries in cancer genetics and genome biology. Yet, with its singular focus on in-depth yet static characterization of primary untreated cancers, TCGA has not captured the dynamic evolution of the cancer genomes in context of metastatic progression and treatments. Although cataloguing the somatic genomic alterations in cancer must continue, it is time for the field to look beyond mining existing data. The next big step will be to put cancer genomics in appropriate clinical context so we can establish complete and longitudinal genomics to phenomics (genotype-phenotype) correlations. Such patient ''big data'' linked to longitudinal clinical information collected during the course of standard of care will accelerate the acquisition of clinically actionable insights. This will involve more than just sequencing in setting of clinical trials. Unlocking the full potential of cancer genomics requires a radical change in the culture of academic medicine to create a new model of collaboration between the basic research and clinical enterprise to ensure the seamless integration of patient-oriented genomic research in context of standard of clinical care so that clinical information and research data are efficiently and accurately collected and linked. Finally, the regulatory environment must support open rolebased data access to enable data-driven discovery and iterative learning between bench and bedside.
Curious World beyond the Genome
Siddhartha Mukherjee
Columbia University ''Curiouser and curiouser'', Alice remarked as she entered a strange, inverted world in Lewis Carrol's classic, Through the Looking Glass. For scientists and physicians, the recent insights provided by leukemia genomes can also be described, rather aptly, as ''curiouser and curiouser''. Take, for instance, the identities of the most frequently mutated genes in acute myelogenous leukemia (AML). A majority are not traditional oncogenes or tumor suppressors. Ras and p53 mutations are mutated, of course, but are far less common than other genes whose functions are mysterious. For example, several labs, including ours, described point mutations in the methyltransferase DNMT3a in AML and in myelodysplastic syndrome. But how does a gene that regulates DNA methylation across the genome ultimately lead to the disordered proliferation, clonal outgrowth, or dysregulated self-renewal of myeloid cells ? Indeed, as this list of genes mutated in AML has grown, this problem of curious identities has also grown more insistent. There are mutations in genes that control metabolism, RNA splicing, myeloid development, and immune function. Where, one might ask, are the good old oncogenes? If there is an unfolding lesson here, it is this: deciphering the cancer genome marks a mere starting line in our attempt to understand cancer. Functionalizing the leukemia genome-understanding what the mutated genes do-is the next major step in tackling cancer. It is likely that this step will be even more labor intensive than deciphering the genome. But we cannot expect new medicines for leukemia to emerge directly from genomic insights. Unlike Alice, who discovered shortcuts, we are stuck with the long way home.
A Million Genomes Ahead
Jun Wang BGI Athough it is definitely a question whether different types of cancer have similar genomic alterations, we do not even have sufficient samples to understand a single type of cancer. Individuals with different genetic and environmental factors, such as carcinogen exposure, commensal or pathogenic bacteria and viruses, life style, and mental health, all have to be sampled, both horizontally and longitudinally. The interpretation of cancer genomes relies on the scale and quality of the sequencing data, innovative handling of such big data and detailed clinical and preclinical information. Early and routine tests would be possible with accurate and ultra-low input next-generation sequencing technologies, which necessitate development of noninvasive sampling approaches. Each sample should be analyzed in a multiomic fashion to be truly reliable and informative. Single-cell sequencing is necessary for elucidating the heterogeneity and reconstructing the evolution of a cancer sample. Biological investigations with optimized humanized mouse models and conditional reprogramming tumors cells would be instrumental for development and evaluation of drugs. Although we envision a million ''personalized'' cancer genomes to come, the hope is to integrate the large-scale, multidimensional data in order to stratify each patient or at-risk individual, for efficient diagnosis, prognosis and treatment.
